Study of two medicines for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18–70 and assigned female at birth
- Your cancer has been confirmed as epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
- Your cancer came back within 6 months after your last platinum chemotherapy
- Testing shows an HRR gene mutation in tumor tissue or a blood sample
- You have at least one measurable spot on scans that the study can track
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), a targeted therapy (bevacizumab), and a PARP inhibitor (fluzoparib) for ovarian cancer that came back at least 6 months after last platinum chemo. It aims to see if this mix helps control the cancer better.
This trial tests whether a combination of two drugs, fluzoparil and apatinib, can help keep ovarian cancer from coming back after platinum chemotherapy. It is for people whose cancer has either returned within 6 months (platinum-resistant) or after 6 months (platinum-sensitive) and who have responded to at least 4 more cycles of chemotherapy.
This trial tests a common chemotherapy (Pegylated Liposomal Doxorubicin) plus an immunotherapy (Adebrelimab), with or without a bladder medication (Mirabegron), in people whose ovarian cancer has returned after initial treatment. The goal is to see if adding Mirabegron helps the other drugs work better.
This early-phase study tests a combination of three medicines to treat ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum chemotherapy, especially when tumors have a BRCA1 or BRCA2 mutation. The goal is to see if this treatment can help control cancer that is hard to treat.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.